Press release
Top Trends Transforming the Direct Oral Anticoagulants (DOACs) Device Market Landscape in 2025: Innovative Automated Assays Enhance Accuracy And Efficiency In Anticoagulant Monitoring
Direct Oral Anticoagulants DOACs Device
What Will the Direct Oral Anticoagulants (DOACs) Device Industry Market Size Be by 2025?
Over the past few years, the market size for direct oral anticoagulants (DOACs) devices has seen significant expansion. A rise from $30.10 billion in 2024 to $32.80 billion in 2025 is projected, representing a compound annual growth rate (CAGR) of 9.0%. The historical growth can be attributed to various factors including an increase in cardiovascular disease cases, a surge in atrial fibrillation incidents, heightened awareness on stroke prevention, a growth in anticoagulant prescriptions and a booming elderly population.
What's the Long-Term Growth Forecast for the Direct Oral Anticoagulants (DOACs) Device Market Size Through 2029?
In the coming years, a significant increase in the market size of direct oral anticoagulants (DOACs) devices is anticipated. The market is forecasted to attain a value of $45.65 billion in 2029, with a compound annual growth rate (CAGR) of 8.6%. The predicted growth in this period can be attributed to multiple factors, including the rising adoption of personalized medicine, the increasing inclination towards home-based anticoagulant management, a surge in demand for quick diagnostic instruments, heightened awareness concerning stroke prevention, and the expansion of healthcare infrastructure in emerging markets. Key trends during the forecast timeline encompass the incorporation of intelligent sensors in monitoring devices, the creation of point-of-care direct oral anticoagulant testing tools, ongoing innovation in drug delivery mechanisms, integration into standard clinical workflows, and advancements in technology related to patient compliance tools.
View the full report here:
https://www.thebusinessresearchcompany.com/report/direct-oral-anticoagulants-doacs-device-global-market-report
What Are the Key Growth Drivers Fueling the Direct Oral Anticoagulants (DOACs) Device Market Expansion?
The escalating occurrence of cardiovascular conditions is forecasted to stimulate the expansion of the direct oral anticoagulants (DOACs) device market in the future. When we speak about cardiovascular issues, we're talking about a variety of diseases that affect the heart and vessels, frequently resulting in complications like heart attacks, strokes, or other circulatory system-related problems. The rise in cardiovascular diseases is attributed to the growing prevalence of inactive lifestyles, which can lead to weight gain, increased blood pressure, and a gradual deterioration of cardiovascular health. Direct oral anticoagulants (DOACs) play a crucial role in managing these illnesses by effectively reducing stroke and blood clot risks among atrial fibrillation patients, ensuring dependable anticoagulation without the need for regular blood tests. For example, the American Heart Association reported that in 2022, cardiovascular diseases were responsible for 941,652 deaths in the US, over 10,000 more than the 931,578 deaths recorded in 2021. As a result, the rising occurrence of cardiovascular diseases is spurring the expansion of the direct oral anticoagulants (DOACs) device market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp
Which Emerging Trends Are Transforming the Direct Oral Anticoagulants (DOACs) Device Market in 2025?
Key entities in the direct oral anticoagulants (DOACs) market are prioritizing the innovation of state-of-the-art solutions including automated coagulation assays. The aim is to bolster the precision, effectiveness, and uniformity of DOAC level monitoring in clinical labs. Automated coagulation assays are machine-conducted laboratory procedures that gauge blood clotting speed to aid in detecting bleeding or clotting problems. For instance, Roche Holding AG, based in Switzerland, introduced three specialized coagulation tests for Factor Xa inhibitors in February 2024. These tests expand doctors' capacity to correctly assess the anticoagulation condition of patients on direct Factor Xa inhibitors like rivaroxaban and apixaban. They contribute to clinical decision making through the exact quantification of the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin in critical scenarios such as bleeding, overdose, or immediate surgery. By employing Roche's reagent cassette technology on cobas t analyzers, these automated assays yield superior results, reduce manual operations, and boost laboratory workflow productivity.
How Is the Direct Oral Anticoagulants (DOACs) Device Market Segmented?
The direct oral anticoagulants (DOACs) device market covered in this report is segmented
1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors
2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases
3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications
4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users
Subsegments:
1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices
2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp
Which Companies Are Leading the Charge in Direct Oral Anticoagulants (DOACs) Device Market Innovation?
Major companies operating in the direct oral anticoagulants (DOACs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy's Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., and DOASENSE GmbH.
Which Regions Are Leading the Global Direct Oral Anticoagulants (DOACs) Device Market in Revenue?
North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2024. The regions covered in the direct oral anticoagulants (DOACs) device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27281
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Speak With Our Expert:
Saumya Sahay,
Americas: +1 310-496-7795,
Asia: +44 7882 955267 & +91 8897263534,
Europe: +44 7882 955267,
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Top Trends Transforming the Direct Oral Anticoagulants (DOACs) Device Market Landscape in 2025: Innovative Automated Assays Enhance Accuracy And Efficiency In Anticoagulant Monitoring here
News-ID: 4171670 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for DOAC
Antiplatelet-Anticoagulant Combination Therapy Market Landscape 2026-2036: Strat …
Future Market Insights (FMI), a leading provider of market intelligence and consulting services, today announced the release of its comprehensive analysis of the Antiplatelet-anticoagulant combination therapy market is projected to reach USD 18,957.6 million by 2035, recording an absolute increase of USD 7,993.3 million over the forecast period. This market is valued at USD 10,964.3 million in 2025 and is set to rise at a CAGR of 6.1% during the…
Direct Oral Anticoagulants Market Insights & Future Opportunities: Growth Driver …
As per the Direct Oral Anticoagulants Market size conducted by the CMI Team, the global Direct Oral Anticoagulants Market is expected to record a CAGR of 7.5% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 32.4 Billion. By 2034, the valuation is anticipated to reach USD 66.8 Billion.
➤ Request a FREE Sample of the Research Report @ https://www.custommarketinsights.com/request-for-free-sample/?reportid=75086
➤ Overview
The global population…
Anticoagulants Market Positioned for Accelerated Development Through 2030, Delve …
DelveInsight's *Anticoagulants Market Insights, Competitive Landscape, and Market Forecast - 2030* report provides a comprehensive analysis of anticoagulants, along with historical and projected market trends worldwide, covering North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
The latest healthcare forecast report provides an in-depth analysis of Anticoagulants, offering comprehensive insights into the Anticoagulants revenue trends, prevalence, and treatment landscape. The report delves into key Anticoagulants statistics, highlighting the…
Anticoagulants Market Statistics Expected to Experience Major Growth by 2032, Ac …
The Key Anticoagulants Companies in the market include - Universitaire Ziekenhuizen KU Leuven, Takeshi Morimoto, Prothya BioSolutions, ARYx Therapeutics, Les Laboratoires, and others.
DelveInsight's "Anticoagulants Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Anticoagulants, historical and forecasted epidemiology as well as the Anticoagulants market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth…
Sales of Anticoagulant are Expected to Reach US$ 65 Billion by the end of 2032, …
By the end of 2021, it's anticipated that anticoagulant sales would total $30 billion USD. According to the report, demand will keep growing and increase by more than two times to reach a value of US$ 65 billion by the conclusion of the evaluation period of 2021-2031.
Players are using online sales channels more frequently to increase their reach while putting out less of a financial investment. The patient pool for…
Anticoagulants Market Revenue Growth Defined by Heightened Product Innovation : …
According to a recently published Fact.MR report, the global anticoagulants market is expected to reach US$ 30 Bn by 2021-end, with an expected value CAGR of 8.04% across the forthcoming decade. Furthermore, the market is expected to close in at US$ 65 Bn by the end of the 2021-2031 assessment period.
Historical performance of the market establishes that the market registered a steady CAGR of 5% from 2016 to 2020. Amidst…
